Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Pinnacle Discovers Silver-Lead-Zinc Mineralization Following up on LiDAR Survey at El Potrero (click to learn more) Sekur Private Data Signs Distribution Agreement In Africa (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Calidi Biotherapeutics Inc CLDI

Alternate Symbol(s):  CLDWW

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high... see more

Current News (NYSEAM:CLDI)

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing

GlobeNewswire 5 days ago

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

GlobeNewswire 7 days ago

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

GlobeNewswire 11 days ago

Calidi Biotherapeutics Announces Proposed Public Offering

GlobeNewswire 11 days ago

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

GlobeNewswire February 20, 2026

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

GlobeNewswire February 12, 2026

Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

GlobeNewswire January 28, 2026

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

GlobeNewswire November 17, 2025

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

GlobeNewswire November 13, 2025
View More News ››

Opinion & Analysis (NYSEAM:CLDI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:CLDI)

Be the first to post on this bullboard.

Boron One Holdings Inc.

Boron One Holdings Inc.

Boron One Holdings Inc. engages in the acquisition, exploration, and development of mineral properties in Serbia. The company ...
View More »

Podcasts